GlassScriptPhysician profile
Chris R Gelvin
NPI 1447244678
$4,655.45
in general payments reported to CMS, 2019-2025
33 companies · $594 in 2025
The $594 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $786 · 2021: $827 · 2022: $322 · 2023: $642 · 2024: $548 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $915.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $703.31 | 2019-2025 | |
| Amgen INC. | $488.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $397.28 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $256.25 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Exact Sciences Corporation | $240.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $233.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $190.92 | 2019-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $153.54 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $153.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $109.62 | 2019-2020 | |
| Eisai INC. | $104.13 | 2020-2022 | |
| Glaxosmithkline, LLC. | $84.78 | 2020-2021 | |
| Amarin Pharma, INC. | $82.73 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.71 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $49.23 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $45.24 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.58 | 2019-2022 | |
| Radius Health, INC. | $38.76 | 2020 | |
| Abbvie INC. | $35.70 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $33.67 | 2019 | |
| Allergan, INC. | $31.26 | 2020 | |
| Alnylam Pharmaceuticals INC. | $27.88 | 2025 | Onpattro |
| Abbott Laboratories | $21.80 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.05 | 2022 | |
| Edwards Lifesciences Corporation | $18.79 | 2020 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.14 | 2019 | |
| Cleerly, INC. | $17.90 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Avanir Pharmaceuticals, INC. | $17.64 | 2019 | |
| Axsome Therapeutics, INC. | $17.29 | 2023 | Auvelity |
| Inogen, INC. | $15.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Gelvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.